NCT06801236View on ClinicalTrials.gov

Phase 1 Study of ACE-232 to Treat Patients With Metastatic Castration-Resistant Prostate Cancer

PHASE1RecruitingINTERVENTIONAL
Enrollment

67

Participants

Timeline

Start Date

May 12, 2025

Primary Completion Date

March 1, 2028

Study Completion Date

August 1, 2028

Conditions
Prostate Cancer (Adenocarcinoma)mCRPC (Metastatic Castration-resistant Prostate Cancer)
Interventions
DRUG

ACE-232 tablets

ACE-232 tablets will be administered orally daily as a continuous regimen together with Dexamethasone and Fludrocortisone. Subjects will continue to receive study treatment until PD as judged by local investigator review, development of unacceptable toxicity, or withdrawal of consent.

Trial Locations (8)

21201

NOT_YET_RECRUITING

University of Maryland, Greenebaum Comprehensive Cancer Center, Baltimore

29572

RECRUITING

Carolina Urologic Research Center, Myrtle Beach

33612

RECRUITING

Moffitt Cancer Center, Tampa, Tampa

55455

RECRUITING

M Health Fairview Clinics and Surgery Center, Minneapolis

68130

RECRUITING

Xcancer (Urology Cancer Center), Omaha

92093

RECRUITING

University of California San Diego, Moores Cancer Center, La Jolla

98109

NOT_YET_RECRUITING

Fred Hutchinson Cancer Research Center, Seattle

02114

NOT_YET_RECRUITING

Harvard Medical School-Massachusetts General Hospital, Boston

All Listed Sponsors
lead

Acerand Therapeutics (Hong Kong) Limited

INDUSTRY